A Multicenter, Randomized, Open-label, Phase 2 Study of Carfilzomib With or Without ARRY-520 in Patients With Advanced Multiple Myeloma

Trial Profile

A Multicenter, Randomized, Open-label, Phase 2 Study of Carfilzomib With or Without ARRY-520 in Patients With Advanced Multiple Myeloma

Completed
Phase of Trial: Phase II

Latest Information Update: 31 Jul 2016

At a glance

  • Drugs Filanesib (Primary) ; Carfilzomib; Dexamethasone; Filgrastim
  • Indications Multiple myeloma
  • Focus Registrational; Therapeutic Use
  • Sponsors Array BioPharma
  • Most Recent Events

    • 01 Jun 2016 Status changed from active, no longer recruiting to completed.
    • 11 Feb 2016 Planned primary completion date changed from 1 Dec 2016 to 1 Feb 2016 as reported by ClinicalTrials.gov.
    • 11 Feb 2016 Planned primary completion date changed from 1 Dec 2015 to 1 Dec 2016 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top